Park Ha Biological Technology Co., Ltd. (BYAH) AI Stock Analysis
BYAH AI stock analysis summary
AI ResearchPark Ha Biological Technology Co., Ltd. is a China-based skincare company operating Product Sales and Franchise Service segments. While revenue grew at a 4-year CAGR of 28.3% to $2.5M in FY2025, net income dropped sharply to -$24.4M. Its shares declined 98.6% over the past year to close at $2.20 as of October 16, 2026.
- Market cap
- $42.9M
- Revenue (TTM)
- $2.5M
- P/E
- —
- 1Y return
- -98.6% S&P 500 16.8%
- Avg. target
- —
Bull case
- The company expanded its gross margin from 66.6% in FY2021 to 94.4% in FY2025.
- Revenue demonstrated a 4-year compound annual growth rate of 28.3% between FY2021 and FY2025.
- As of April 30, 2026, the balance sheet maintained net cash of $5.5M with a low debt-to-equity ratio of 0.03.
Bear case
- Net income dropped sharply to -$24.4M in FY2025, driving the net margin down to -965.0%.
- The stock experienced a severe 1-year decline of 98.6%, falling from a 52-week high of $169.60 to $2.20 as of October 16, 2026.
- The company trades at a price-to-sales multiple of 16.9x, significantly higher than the US-listed Consumer Defensive peer median of 0.7x.
What Park Ha Biological Technology does
Park Ha Biological Technology Co., Ltd. is an investment holding company that develops skincare products in the People's Republic of China. Operating through Product Sales and Franchise Service segments, the company offers skincare solutions ranging from basic physical skin protection, exfoliation, and sebum film repair to microecological balance and anti-aging under the Park Ha brand. Products are distributed through directly operated retail stores and franchisees. Headquartered in Wuxi, China, the company operates as a subsidiary of Xiaoqiu Holding Ltd. and maintains strategic partnerships with Star Plus Action (HK) Limited and Cloud Factory Technology Holdings Limited to build AI-driven beauty ecosystems.
Growth and profitability
From FY2021 to FY2025, revenue increased from $931,036 to $2.5M, reflecting a 4-year CAGR of 28.3%. Gross margin expanded over the period from 66.6% in FY2021 to 94.4% in FY2025. After posting net income of $191,298 in FY2022, $852,042 in FY2023, and $478,561 in FY2024, profitability deteriorated in FY2025 with a net loss of -$24.4M and an operating margin of -956.5%. For the trailing twelve months ended April 30, 2026, revenue stood at $2.5M with a quarterly revenue growth YoY of 1.5% and a profit margin of -214.2%.
Balance sheet and cash flow
As of April 30, 2026, the company held $5.7M in cash and short-term investments against total debt of $186,330, resulting in net cash of $5.5M. Total assets were $7.5M and shareholders' equity was $5.4M, supported by a current ratio of 3.36 and a debt-to-equity ratio of 0.03. Operating cash flow in FY2025 was $85,852, while capital expenditures were $88,822, leading to free cash flow of -$2,970.
Valuation and performance
Park Ha Biological Technology Co., Ltd. trades at a price-to-sales multiple of 16.9x, compared to the median of 0.7x for its US-listed Consumer Defensive peers. Its EV-to-EBITDA stands at 15.5x, above the peer group median of 11.7x, alongside a price-to-book ratio of 0.4x and a market capitalization of $42.9M. The stock has underperformed the broader market, dropping 98.6% over the past year compared to a 16.8% gain for the S&P 500 (SPY), and sits 84.3% below its 200-day average.
What analysts expect
There are no consensus analyst price targets, ratings, or forward earnings estimates available for Park Ha Biological Technology Co., Ltd. Insiders hold 30.1% of the shares, while institutional investors account for 0.2%, and short interest is 0.1% of float. Over the trailing twelve months ended April 30, 2026, the company recorded diluted EPS of -$37.68. The stock closed at $2.20 on October 16, 2026, down significantly from its 52-week high of $169.60.
Key risks and what to watch
- Profitability remains deeply negative, evidenced by a trailing twelve month profit margin of -214.2% and EPS of -$37.68.
- Free cash flow declined from $874,901 in FY2024 to -$2,970 in FY2025, highlighting cash generation volatility.
- Top-line expansion has slowed significantly, with quarterly revenue growth YoY registering at 1.5% as of April 30, 2026.
- Trading momentum is severely depressed, with the share price standing 84.3% below its 200-day average.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this BYAH AI stock analysis
This page is an AI-written research summary of Park Ha Biological Technology Co., Ltd. (BYAH). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: BYAH income statement, BYAH balance sheet, BYAH key metrics, BYAH chart. See the BYAH stock overview for the latest quote and news.
BYAH AI stock analysis FAQ
What does Park Ha Biological Technology Co., Ltd. do?
Founded in 2016 and based in Wuxi, China, the company develops and sells skincare products across Product Sales and Franchise Service segments under the Park Ha brand. It operates retail stores and franchises and has partnerships to develop AI-driven beauty ecosystems.
Does BYAH pay a dividend?
Park Ha Biological Technology Co., Ltd. does not pay a dividend.
How much cash and debt does BYAH have?
As of April 30, 2026, the company held $5.7M in cash and short-term investments and $186,330 in total debt, yielding a net cash position of $5.5M.
What was BYAH's net income in FY2025?
In FY2025, the company posted a net loss of -$24.4M, compared to net income of $478,561 in FY2024.
How has BYAH stock performed recently?
As of October 16, 2026, the stock closed at $2.20, down 96.5% year-to-date and 98.6% over the trailing one-year period.